Inc () CEO Saiid Zarrabian tells Proactive that its drug VAL-083 has been activated for an adaptive platform recurrent glioblastoma (GBM) trial.
Zarrabian says Kintara, along with Kazia Therapeutics Limited () () and its drug paxalisib, will collaborate with the Global Coalition for Adaptive Research and are entering the GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) trial that opened in July and has screened more than 370 patients to date.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Kintara Therapeutics named herein, including the promotion by the Company of Kintara Therapeutics in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
